Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bile acid breakthrough: could a Decades-Old pill stop c. diff in its tracks?

NCT ID NCT06884748

Not yet recruiting Prevention Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether adding Ursodeoxycholic Acid (UDCA) to standard antibiotics can prevent Clostridioides difficile (C. diff) infection from returning. About 30 adults with C. diff and risk factors for recurrence will take UDCA three times daily for up to eight weeks alongside their usual antibiotics. Researchers will monitor stool tests and symptoms to see if UDCA reduces recurrence and the need for more antibiotics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLOSTRIDIOIDES DIFFICILE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis Clostridium infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLOSTRIDIOIDES DIFFICILE INFECTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Daniel Stein

    Milwaukee, Wisconsin, 53226, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.